GoodRx Holdings, Inc. (GDRX)

Financial Performance & Trajectory

GoodRx’s revenue trajectory has effectively flatlined, with trailing revenue stabilizing at $0.80B and YoY growth decelerating to just 0.5% in Q1 2026 from 0.6% in the prior two quarters. This stagnation signals a mature, largely tapped market for its core prescription savings platform, with little to no top-line expansion. However, the company demonstrates strong cash generation discipline. While gross margin data is unavailable, free cash flow (FCF) margins have shown notable improvement, jumping from 11.8% in Q1 2026 to a robust 20.6% in Q4 and Q3 2025. This suggests a deliberate shift from growth-at-all-costs to profitability-focused operations, effectively converting a high percentage of revenue into free cash flow despite the lack of revenue growth.

Operational & Go-to-Market (GTM) Efficiency

The Rule of 40 score—a combined metric of growth and FCF margin—remains a key area of concern, hovering at a weak 12.3 in Q1 2026, up from 21.2 in Q4 2025. This decline reflects the severe growth deficit; the score is almost entirely dependent on FCF margins, not revenue expansion. The absence of Net Revenue Retention (NRR) and CAC Payback data leaves a gap in evaluating customer stickiness and GTM spend efficiency. Given the revenue plateau, it is likely that customer acquisition costs are not yielding incremental revenue, and reinvestment in R&D appears to be focused on cost optimization rather than driving new, high-growth revenue streams. The operational model is currently optimized for cash generation, not for top-line acceleration.

Market Valuation & Sentiment

At a 1.3x EV/Revenue multiple (Q1 2026), GoodRx trades at a discount reflective of its low-growth profile, slightly above the 1.1x seen in Q4 2025. This multiple is typical for a slow-growth or no-growth SaaS business but is not distressed. Insider activity reveals a net selling position of -$90.3K over the last 10 filings, with zero buys, indicating a lack of internal conviction in near-term upside. Wall Street sentiment is cautious, with a consensus Hold rating (10 Buys, 13 Holds, 1 Sell) and an average price target of $3.25. This target implies limited upside from current levels, aligning with a market view that GoodRx is a cash-generating value stock rather than a growth re-acceleration story, warranting a neutral but watchful stance.